Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm caused by a reciprocal
translocation [t (9; 22)(q34; q11. 2)] that leads to the fusion of ABL1 gene sequences (9q34) …

Most reports on chronic myeloid leukaemia (CML) treatment with tyrosine kinase inhibitors
(TKIs) focus on efficacy, particularly on molecular response and outcome. In contrast …

Patients with chronic myeloid leukemia in chronic phase (CML-CP) resistant/intolerant to≥ 2
tyrosine kinase inhibitors (TKIs) are at high risk of experiencing poor outcomes because of …

The NCCN Guidelines for Acute Lymphoblastic Leukemia (ALL) focus on the classification of
ALL subtypes based on immunophenotype and cytogenetic/molecular markers; risk …

Chronic myeloid leukemia (CML) is defined by the presence of Philadelphia chromosome
(Ph) which results from a reciprocal translocation between chromosomes 9 and 22 [t (9; 22] …

Advances in chronic myeloid leukemia treatment, particularly regarding tyrosine kinase
inhibitors, mandate regular updating of concepts and management. A European …

The TYRO3, AXL (also known as UFO) and MERTK (TAM) family of receptor tyrosine
kinases (RTKs) are aberrantly expressed in multiple haematological and epithelial …

Background Ponatinib is a potent oral tyrosine kinase inhibitor of unmutated and mutated
BCR-ABL, including BCR-ABL with the tyrosine kinase inhibitor–refractory threonine-to …

The outbreak of COVID-19, the pandemic disease caused by the severe acute respiratory
syndrome coronavirus 2 (SARS-CoV-2), has spurred an intense search for treatments by the …

Molecular targeted therapy for cancer has been a research hotspot for decades. AXL is a
member of the TAM family with the high-affinity ligand growth arrest-specific protein 6 …